Your browser doesn't support javascript.
loading
Evaluation of the Nigeria national HIV rapid testing algorithm.
Iriemenam, Nnaemeka C; Mpamugo, Augustine; Ikpeazu, Akudo; Okunoye, Olumide O; Onokevbagbe, Edewede; Bassey, Orji O; Tapdiyel, Jelpe; Alagi, Matthias A; Meribe, Chidozie; Ahmed, Mukhtar L; Ikwulono, Gabriel; Aguolu, Rose; Ashefor, Gregory; Nzelu, Charles; Ehoche, Akipu; Ezra, Babatunde; Obioha, Christine; Baffa Sule, Ibrahim; Adedokun, Oluwasanmi; Mba, Nwando; Ihekweazu, Chikwe; Charurat, Manhattan; Lindsay, Brianna; Stafford, Kristen A; Ibrahim, Dalhatu; Swaminathan, Mahesh; Yufenyuy, Ernest L; Parekh, Bharat S; Adebajo, Sylvia; Abimiku, Alash'le; Okoye, McPaul I.
Afiliación
  • Iriemenam NC; Division of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Federal Capital Territory, Nigeria.
  • Mpamugo A; Center for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Baltimore, Federal Capital Territory, Nigeria.
  • Ikpeazu A; Federal Ministry of Health, Abuja, Federal Capital Territory, Nigeria.
  • Okunoye OO; Division of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Federal Capital Territory, Nigeria.
  • Onokevbagbe E; Center for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Baltimore, Federal Capital Territory, Nigeria.
  • Bassey OO; Division of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Federal Capital Territory, Nigeria.
  • Tapdiyel J; Division of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Federal Capital Territory, Nigeria.
  • Alagi MA; Division of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Federal Capital Territory, Nigeria.
  • Meribe C; Division of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Federal Capital Territory, Nigeria.
  • Ahmed ML; Division of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Federal Capital Territory, Nigeria.
  • Ikwulono G; Federal Ministry of Health, Abuja, Federal Capital Territory, Nigeria.
  • Aguolu R; National Agency for the Control of AIDS, Abuja, Federal Capital Territory, Nigeria.
  • Ashefor G; National Agency for the Control of AIDS, Abuja, Federal Capital Territory, Nigeria.
  • Nzelu C; Federal Ministry of Health, Abuja, Federal Capital Territory, Nigeria.
  • Ehoche A; Center for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Baltimore, Federal Capital Territory, Nigeria.
  • Ezra B; Center for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Baltimore, Federal Capital Territory, Nigeria.
  • Obioha C; Center for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Baltimore, Federal Capital Territory, Nigeria.
  • Baffa Sule I; Center for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Baltimore, Federal Capital Territory, Nigeria.
  • Adedokun O; Center for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Baltimore, Federal Capital Territory, Nigeria.
  • Mba N; National Reference Laboratory, Nigeria Centers for Disease Control, Gaduwa, Federal Capital Territory, Nigeria.
  • Ihekweazu C; National Reference Laboratory, Nigeria Centers for Disease Control, Gaduwa, Federal Capital Territory, Nigeria.
  • Charurat M; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
  • Lindsay B; Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
  • Stafford KA; Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
  • Ibrahim D; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
  • Swaminathan M; Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
  • Yufenyuy EL; Division of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Federal Capital Territory, Nigeria.
  • Parekh BS; Division of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Federal Capital Territory, Nigeria.
  • Adebajo S; International Laboratory Branch, Division of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Abimiku A; International Laboratory Branch, Division of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Okoye MI; Center for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation - an affiliate of the University of Maryland, Baltimore, Federal Capital Territory, Nigeria.
PLOS Glob Public Health ; 2(11): e0001077, 2022.
Article en En | MEDLINE | ID: mdl-36962660
ABSTRACT
Human Immunodeficiency Virus (HIV) diagnosis remains the gateway to HIV care and treatment. However, due to changes in HIV prevalence and testing coverage across different geopolitical zones, it is crucial to evaluate the national HIV testing algorithm as false positivity due to low prevalence could be detrimental to both the client and the service delivery. Therefore, we evaluated the performance of the national HIV rapid testing algorithm using specimens collected from multiple HIV testing services (HTS) sites and compared the results from different HIV prevalence levels across the six geopolitical zones of Nigeria. The evaluation employed a dual approach, retrospective, and prospective. The retrospective evaluation focused on a desktop review of program data (n = 492,880) collated from patients attending routine HTS from six geopolitical zones of Nigeria between January 2017 and December 2019. The prospective component utilized samples (n = 2,895) collected from the field at the HTS and tested using the current national serial HIV rapid testing algorithm. These samples were transported to the National Reference Laboratory (NRL), Abuja, and were re-tested using the national HIV rapid testing algorithm and HIV-1/2 supplementary assays (Geenius to confirm positives and resolve discordance and multiplex assay). The retrospective component of the study revealed that the overall proportion of HIV positives, based on the selected areas, was 5.7% (28,319/492,880) within the study period, and the discordant rate between tests 1 and 2 was 1.1%. The prospective component of the study indicated no significant differences between the test performed at the field using the national HIV rapid testing algorithm and the re-testing performed at the NRL. The comparison between the test performed at the field using the national HIV rapid testing algorithm and Geenius HIV-1/2 supplementary assay showed an agreement rate of 95.2%, while that of the NRL was 99.3%. In addition, the comparison of the field results with HIV multiplex assay indicated a sensitivity of 96.6%, the specificity of 98.2%, PPV of 97.0%, and Kappa Statistic of 0.95, and that of the NRL with HIV multiplex assay was 99.2%, 99.4%, 99.0%, and 0.99, respectively. Results show that the Nigeria national serial HIV rapid testing algorithm performed very well across the target settings. However, the algorithm's performance in the field was lower than the performance outcomes under a controlled environment in the NRL. There is a need to target testers in the field for routine continuous quality improvement implementation, including refresher trainings as necessary.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: PLOS Glob Public Health Año: 2022 Tipo del documento: Article País de afiliación: Nigeria

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: PLOS Glob Public Health Año: 2022 Tipo del documento: Article País de afiliación: Nigeria